WT1 Our panel, mainly CNV-based, covers most of the chromosomal regions and candidate genes which have been reported to associate with neuroblastoma. We developed the panel to select 3 large chromosomal regions(17q, 11q and 1p36) that are most reported and others associated with MYCN amplification or not, including MYCN itself and ALK, DDX, CDK4, CDK6, MDM2, CCND1, FGFR4, GLI1, NBAS, ODC1, OS9, YEATS4, deleted on ATRX, ARID1A, ARID1B, CDKN2A, CDKN1C, H19, IGF2, RBMS3, PTEN, PTPRD, TIAM1 and NF1. In order to expand the screening of somatic mutations of neuroblastoma, the panel we designed also includes important genes with somatic mutations found previously in neuroblastoma, for example, PTPN11, PHOX2B, BARD1, PTCH1, TP53, CHEK2, BRCA1, BRCA2, HRAS, KRAS, NRAS, PIK3CA and BRAF. Overall, our neuroblastoma panel, spans 53 genes and 3 large chromosome regions. Description: The gray shade is the area that is captured based on the CNVs, and the other is the capture area based on the point mutations. All of the 33 tissue and leukocyte samples sequenced were then subjected to stringent QC allegations. The mean coverage depth in all of the target regions in all of the samples was 887×, and the mapped read percentage was over 99%. The imputed insert size and library complexity statistics shown in Supplementary Figure 1 revealed a mean insert size of 212 bp, and these findings indicated a high capture efficiency of the probes.
Supplementary Table 3:
The detailed quality control data of 33 samples. See Supplementary_Table_3. 
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